List view / Grid view
21 October 2015 | By Victoria White
Until this orphan drug approval, no specific coagulation factor replacement therapy was available in the US for patients with hereditary Factor X deficiency...
21 October 2015 | By Victoria White
The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis did not achieve its primary and secondary endpoints...
21 October 2015 | By Victoria White
The results come from two head-to-head studies directly comparing the efficacy and safety of umeclidinium to two available bronchodilator treatments...
21 October 2015 | By Victoria White
Novartis is broadening its portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation...
20 October 2015 | By Victoria White
The 2015 UNESCO-Merck Africa Research Summit will focus on the role of building capacities in the life sciences to address challenges of infectious diseases, most notably the Ebola crises...
20 October 2015 | By Victoria White
Commercial production will begin at the new state-of-the-art site early next year and will focus on final-stage manufacturing, packaging and quality control...
20 October 2015 | By Victoria White
The treatment market for multiple myeloma across China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021...
20 October 2015 | By Victoria White
New Phase 3 data show treatment with Janssen’s Stelara (ustekinumab) induced clinical response and clinical remission in patients with moderate to severe Crohn's disease who had previously failed conventional therapy.
20 October 2015 | By Victoria White
In the trial, a significantly greater proportion of patients on Ozanimod achieved or maintained clinical remission at 32 weeks compared with those on placebo...
19 October 2015 | By Victoria White
Nilotinib, a treatment for leukaemia, improved cognition, motor skills and non-motor function in patients with Parkinson's disease in a Phase I clinical trial...
19 October 2015 | By Victoria White
Daiichi Sankyo has said that it will reorganise its US commercial operations from a maturing primary care product portfolio to a differentiated specialty portfolio...
19 October 2015 | By Victoria White
Pfizer’s investigational antibody-drug conjugate inotuzumab ozogamicin has received Breakthrough Therapy designation for acute lymphoblastic leukaemia...
19 October 2015 | By Victoria White
The global treatment market for peripheral artery disease will hit a peak of $983.6 million in 2020, before falling to $816.3 million by 2024 due to the generic erosion of Brilinta and Xarelto...
19 October 2015 | By Victoria White
Praxbind is indicated for patients treated with Pradaxa, when reversal of the anticoagulant effects of Pradaxa is needed for emergency surgery or in uncontrolled bleeding...
19 October 2015 | By Victoria White
Viekirax and Exviera are the first treatments for chronic HCV to combine three direct-acting antiviral agents to target the infection at multiple steps in the viral lifecycle...
